Hifibio Therapeutics Closes $75 Million Series D Financing To Accelerate Pipeline With Two Lead Immuno-Oncology Programs And Validate Its Dis™ Approach In The Clinic
Hifibio Therapeutics Closes $75 Million Series D Financing To Accelerate Pipeline With Two Lead Immuno-Oncology Programs And Validate Its Dis™ Approach In The Clinic
06/14/21, 12:07 PM
Location
cambridgeMoney raised
$75 million
Round Type
series d
HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and drug intelligent science, today announced the completion of an oversubscribed $75M Series D financing round. The funding was led by the new investor Mirae Asset Financial Group. Further, B Capital Group, Sherpa, Maison Capital, Trinity Innovation Fund, Grand Mount, and HKSTP Venture Fund also participated in this round. The existing shareholders IDG, Sequoia, Legend Star, and Hengxu continued to invest.
Company Info
Location
cambridge, maryland, united states
Additional Info
HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to address unmet medical needs around the world through open-innovation partnerships with industry and academia. The company features a strong global footprint with cutting-edge laboratories on three continents in Cambridge, Mass., Paris, France, Shanghai, Hong Kong, and Hangzhou in China. For more information, please visit www.hifibio.com.
1 HFB30132A is an investigational agent. Safety and Efficacy have not been established. There is no guarantee that HFB30132A will become approved and commercially available anywhere globally.